2Langleben D,Barst R J,Badesch D,et al.Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension.Circulation,1999,99(25):3266-3271.
4Channick RN,Simonneau G,Sitbon O,et al.Effects of the dual endothelin-receptor antagonist bosentan in patient with pulmonary hypertension: a randomized placebo-controlled study.Lancet,2001,358(9288):1119-1123.
5Williamson DJ,Wallman LL,Jones R,et al.Hemodynamic effects of bosentan,an endothelin receptor antagonist,in patients with pulmonary hypertension.Circulation,2000,102(4):411-418.
6Barst RJ,Rich S,Widitz A,et al.Clinical efficacy of sitaxsentan,an endothelin a receptor antagonist,in patients with pulmonary arterial hypertension: Open-label pilot study.Chest,2002,121(6):1860-1868.
7Trulock EP.Lung transplantation for primary pulmonary hypertension.Clin Chest Med,2001,22(3):583-593.
8Lane KB,Machado RD,Pauciulo MW,et al.Heterozygous germline mutations in BMPR2,encoding a TGF-beta receptor,cause familial primary pulmonary hypertension.Nat Genet,2000,26(1):81-84.
9Thomson JR,Machado RD,Pauciulo MW,et al.Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II,a receptor member of the TGF-beta family.J Med Genet,2000,37(10):741-745.
